+10.9%
DIS vs MRNA
+915.3%
-904.4%
-60.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.6% | -3.4% | +4.1% | +0.7% |
| 7D | +1.9% | -12.1% | +14.0% | +2.3% |
| 30D | +9.2% | -1.3% | +10.5% | +9.1% |
| 3M | +13.5% | +250.9% | -237.4% | +5.6% |
| 6M | +14.3% | +343.0% | -328.7% | +4.7% |
| YTD | +5.4% | +657.4% | -652.1% | -6.1% |
| 1Y | +12.2% | +794.9% | -782.8% | -0.9% |
| 3Y | +37.2% | +218.1% | -181.0% | +24.1% |
| 5Y | -23.1% | -3.4% | -19.7% | -29.5% |
| All | +10.9% | +915.3% | -904.4% | +4.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling